An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study
PLOS Neglected Tropical Diseases · 2024
DOI: 10.1371/journal.pntd.0011910 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Manuel Abal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigaciones Biotecnológicas (IIBio), Universidad Nacional de San Martín (UNSAM), and Consejo Nacional de Investigaciones Científicas…. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Chagas Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Agencia Nacional de Promoción Científica y Tecnológica, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background Proper evaluation of therapeutic responses in Chagas disease is hampered by the prolonged persistence of antibodies to Trypanosoma cruzi measured by conventional serological tests and by the lack of sensitivity of parasitological tests. Previous studies indicated that tGPI-mucins, an α-Gal (α- d -Gal p (1→3)-β- d -Gal p (1→4)- d -GlcNAc)-rich fraction obtained from T . cruzi trypomastigotes surface coat, elicit a strong and protective antibody response in infected individuals, which disappears soon after successful treatment. The cost and technical difficulties associated with tGPI-mucins preparation, however, preclude its routine implementation in clinical settings. Methods/principle findings We herein developed a neoglycoprotein consisting of a BSA scaffold decorated with several units of a synthetic α-Gal antigenic surrogate (α- d -Gal p (1→3)-β- d -Gal p (1→4)-β- d -Glc p ). Serological responses to this reagent, termed NGP-Tri, were monitored by means of an in-house enzyme-linked immunosorbent assay (α-Gal-ELISA) in a cohort of 82 T . cruzi -infected and Benznidazole- or Nifurtimox-treated children (3 days to 16 years-old). This cohort was split into 3 groups based on the age of patients at the time of treatment initiation: Group 1 comprised 24 babies (3 days to 5 months-old; median = 26 days-old), Group 2 comprised 31 children (7 months to 3 years-old; median = 1.0-year-old) and Group 3 comprised 26 patients (3 to 16 years-old; median = 8.4 years-old). A second, control cohort (Group 4) included 39 non-infected infants (3 days to 5 months-old; median = 31 days-old) born to T . cruzi -infected mothers. Despite its suboptimal seroprevalence (58.4%), α-Gal-ELISA yielded shorter median time values of negativization (23 months [IC 95% 7 to 36 months] vs 60 months [IC 95% 15 to 83 months]; p = 0.0016) and higher rate of patient negative seroconversion (89.2% vs 43.2%, p < 0.005) as compared to conventional serological methods. The same effect was verified for every Group, when analyzed separately. Most remarkably, 14 out of 24 (58.3%) patients from Group 3 achieved negative seroconversion for α-Gal-ELISA while none of them were able to negativize for conventional serology. Detailed analysis of patients showing unconventional serological responses suggested that, in addition to providing a novel tool to shorten follow-up periods after chemotherapy, the α-Gal-ELISA may assist in other diagnostic needs in pediatric Chagas disease. Conclusions/significance The tools evaluated here provide the cornerstone for the development of an efficacious, reliable, and straightforward post-therapeutic marker for pediatric Chagas disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Instituto de Investigaciones Biotecnológicas (IIBio), Universidad Nacional de San Martín (UNSAM), and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
- Escuela de Bio y Nanotecnologías (EByN), UNSAM, Buenos Aires, Argentina.
- Centro de Investigaciones en Hidratos de Carbono (CIHIDECAR), Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), and CONICET, Buenos Aires, Argentina.
- Servicio de Parasitología-Chagas, Hospital de Niños 'Dr Ricardo Gutierrez', and Instituto Multidisciplinario en Investigaciones Pediátricas (IMIPP) CONICET-GCBA, Buenos Aires, Argentina.
- Mahidol Oxford Research Unit (MORU), Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom.
- Fundación para el estudio de las infecciones parasitarias y enfermedad de Chagas (FIPEC foundation), Buenos Aires, Argentina.
ORCID-Profile: Carlos A Buscaglia
Förderung
- Wellcome Trust
- Agencia Nacional de Promoción Científica y Tecnológica
- Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
Zitieren
APA
Abal, M., Balouz, V., Lopez, R., Giorgi, M. E., Marino, C., Cruz, C. V., Altcheh, J., & Buscaglia, C. A. (2024). An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011910
Vancouver
Abal M, Balouz V, Lopez R, Giorgi ME, Marino C, Cruz CV, et al. An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0011910
BibTeX
@article{Abal2024,
author = {Abal, Manuel and Balouz, Virginia and Lopez, Rosana and Giorgi, M Eugenia and Marino, Carla and Cruz, Cintia V and Altcheh, Jaime and Buscaglia, Carlos A},
title = {An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study},
journal = {PLOS Neglected Tropical Diseases},
year = {2024},
doi = {10.1371/journal.pntd.0011910}
}
EUVIMED